FSH: What This Test Actually Measures and What Your Results Mean

What FSH actually measures (and why "it measures fertility" is too simple)

FSH, or follicle-stimulating hormone, is a glycoprotein produced by the anterior pituitary gland in your brain. Its job is to recruit and mature ovarian follicles, the fluid-filled sacs that each contain one egg. The test measures the concentration of FSH in your blood at a single moment in time, reported in milli-international units per milliliter (mIU/mL).

Here is the part most lab result explainers skip: FSH does not directly tell you how many eggs you have. It tells you how loudly your brain is shouting at your ovaries. When your ovaries respond well, they produce estradiol and inhibin B, which feed back to the pituitary and suppress FSH. When ovarian response weakens, that feedback loop breaks down, FSH climbs, and the pituitary shouts louder trying to compensate.

That feedback loop is the reason FSH is simultaneously a fertility marker, a perimenopause marker, and a pituitary function marker, depending on context and your life stage.

The hypothalamic-pituitary-ovarian axis in plain language

Your hypothalamus releases GnRH (gonadotropin-releasing hormone) in pulses. Each GnRH pulse prompts your pituitary to release FSH and LH (luteinizing hormone). FSH drives follicle recruitment; LH triggers the ovulation surge. As the dominant follicle grows, estradiol rises, which initially suppresses FSH (negative feedback) but then, at a threshold, triggers the LH surge (positive feedback). After ovulation, the corpus luteum produces progesterone, further suppressing FSH until the next cycle begins.

This explains why FSH is almost always drawn on cycle day 2 or 3, at the start of your period, before any follicle has grown large enough to suppress it. A day-10 FSH result tells you almost nothing clinically useful.

Why FSH is different from AMH

Anti-Müllerian hormone (AMH) is produced directly by small antral follicles and reflects the size of your remaining egg pool more accurately than FSH does. AMH can be drawn on any cycle day. FSH, by contrast, reflects the pituitary's response to declining ovarian reserve, which means it rises later in the process. A woman may have a reassuringly normal FSH but a low AMH, indicating early decline in egg quantity before FSH has risen to signal it. The American Society for Reproductive Medicine notes that no single test fully characterizes ovarian reserve and that FSH, AMH, and antral follicle count should be interpreted together.

Normal FSH ranges by life stage

There is no single "normal." FSH ranges shift across your entire reproductive life, and the reference range printed on your lab report may not match your clinical situation.

Reproductive years (cycle day 2-3)

For women aged roughly 18-37, a day-2 or day-3 FSH of 3-10 mIU/mL is generally considered normal, though many reproductive endocrinologists use a threshold of <10 mIU/mL as reassuring. Values between 10-15 mIU/mL may suggest diminished ovarian reserve; values above 15-20 mIU/mL in this age group warrant closer evaluation. Individual lab reference ranges vary, so always interpret your number in context with your provider, not against the printed range alone.

Mid-cycle LH surge

FSH also rises at mid-cycle, coinciding with the LH surge and ovulation. A mid-cycle FSH draw is not used for ovarian reserve testing. If your provider ordered FSH to assess reserve and drew it on day 14, ask to repeat on day 2-3.

Perimenopause

FSH becomes erratic years before the final menstrual period. It may be elevated one cycle and normal the next. The Menopause Society (formerly NAMS) states that menopause is defined clinically by 12 consecutive months of amenorrhea, not by FSH alone, because FSH fluctuates too much in perimenopause to be diagnostic on a single reading. Two FSH values above 25-30 mIU/mL drawn at least six weeks apart, combined with symptoms, support a perimenopause or menopause diagnosis.

Postmenopause

After menopause, estradiol falls to very low levels and the pituitary, no longer suppressed, produces FSH persistently at high levels. Postmenopausal FSH typically ranges from 25 to 135 mIU/mL, depending on the lab assay. A postmenopausal woman does not need repeated FSH checks unless there is a clinical question about pituitary function or she is restarting a hormonal therapy that might suppress FSH.

Pregnancy

FSH drops to near-zero in pregnancy. The placenta produces hCG, which takes over ovarian stimulation via the LH receptor. Testing FSH in pregnancy has no clinical utility.

Childhood and puberty

Before puberty, FSH is very low (typically <2 mIU/mL). It begins rising during the early stages of puberty as the hypothalamic-pituitary axis activates. Abnormally low FSH in a teenager who has not entered puberty by age 13 or abnormally high FSH in a child before age 8 may indicate precocious puberty or a pituitary problem and warrants pediatric endocrinology referral.

What high FSH means for women

A high FSH is your pituitary signaling urgently to ovaries that are not responding as expected. The clinical meaning depends heavily on your age and where you are in your cycle.

High FSH in your 20s and 30s: primary ovarian insufficiency

Primary ovarian insufficiency (POI) affects approximately 1 in 100 women under 40. It is defined by menstrual irregularity and an FSH above 25 mIU/mL on two occasions at least four weeks apart, before age 40. POI is not the same as premature menopause; about 5-10% of women with POI will conceive spontaneously. Causes include autoimmune conditions (check thyroid antibodies and adrenal antibodies), genetic factors such as Fragile X premutation, prior chemotherapy, radiation, or surgery.

Women with POI should have karyotype testing and Fragile X carrier screening. They are at significantly elevated risk of osteoporosis due to prolonged estrogen deficiency, and ACOG recommends hormone therapy until the average age of natural menopause (around 51) to protect bone, cardiovascular, and cognitive health.

High FSH in perimenopause

In the menopausal transition, rising and fluctuating FSH is expected. The SWAN (Study of Women's Health Across the Nation) cohort data showed that FSH begins rising an average of five to eight years before the final menstrual period. Women in their mid-40s with FSH above 10-12 mIU/mL and cycle changes should be counseled that they may be in early perimenopause, even if FSH has not yet crossed the 25 mIU/mL threshold.

High FSH and PCOS: a case where FSH is usually normal or low

Women with polycystic ovary syndrome (PCOS) typically have a normal or mildly low FSH with an elevated LH/FSH ratio (classically greater than 2:1 or 3:1), reflecting the altered pituitary signaling pattern in PCOS. If a woman with suspected PCOS has a high FSH, that warrants reassessment of the diagnosis. PCOS does not cause high FSH.

Can high FSH be treated or lowered?

This is one of the most searched questions about FSH, and the answer is: lowering the number does not fix the underlying problem. FSH is a signal, not a cause. Certain supplements (DHEA, CoQ10) and acupuncture are marketed for "lowering FSH," but no high-quality randomized controlled trial has shown that reducing FSH in women with POI or diminished ovarian reserve improves live birth rates. A lower FSH number after a supplement does not mean ovarian reserve has improved; it may simply reflect assay variability or cycle-to-cycle fluctuation. Discuss any supplement use with your reproductive endocrinologist before a fertility cycle, because some supplements affect FSH suppression in ways that complicate protocol planning.

What low FSH means for women

Low FSH means the pituitary is not sending enough signal to the ovaries. This is called hypogonadotropic hypogonadism, meaning low gonadotropins (FSH and LH) are failing to stimulate the gonads.

Functional hypothalamic amenorrhea

The most common cause of low FSH in otherwise healthy reproductive-age women is functional hypothalamic amenorrhea (FHA), a condition in which the hypothalamus downregulates GnRH pulsing in response to energy deficit, excessive exercise, psychological stress, or low body weight. The Endocrine Society Clinical Practice Guideline on FHA characterizes it by FSH below 5 mIU/mL with low or low-normal LH, low estradiol, and absent periods. Bone loss begins within months of estrogen deficiency in FHA.

Treatment targets the root cause: restoring caloric balance, reducing training load, and addressing psychological contributors. FSH and ovarian function typically recover when energy availability is restored.

Hyperprolactinemia

High prolactin (from a pituitary adenoma or medications including antipsychotics, metoclopramide, and some antidepressants) suppresses GnRH pulsing and thus lowers FSH and LH. Always check prolactin when FSH is low and periods are absent or irregular.

Pituitary or hypothalamic disease

Tumors, infiltrative diseases (sarcoidosis, hemochromatosis), head trauma, and radiation to the skull base can damage FSH-producing cells. An MRI of the pituitary is indicated when FSH is unexpectedly low, especially with headache or visual field changes.

Trying to conceive with low FSH

If low FSH is preventing ovulation, fertility treatment involves stimulating the pituitary or bypassing it entirely with injectable FSH (gonadotropins). Women with FHA who want to conceive may respond to pulsatile GnRH therapy or low-dose gonadotropin stimulation once nutritional rehabilitation has begun.

FSH across female-specific conditions

The table below organizes FSH patterns by the conditions most relevant to women's health, a cross-reference that is not available in standard lab-result guides.

| Condition | Typical FSH pattern | What to do next | |---|---|---| | PCOS | Normal to mildly low; LH/FSH ratio >2 | Check LH, testosterone, AMH, fasting insulin | | Primary ovarian insufficiency | >25 mIU/mL on two occasions <40 years | Karyotype, Fragile X, autoimmune panel, bone density | | Functional hypothalamic amenorrhea | <5 mIU/mL with low LH, low estradiol | Nutritional assessment, sports medicine, psychological support | | Perimenopause | Fluctuating, trending upward; may exceed 25 | Symptom history; repeat in 6 weeks if borderline | | Postmenopause | 25-135 mIU/mL, stable | No repeat needed unless pituitary disease suspected | | Hyperprolactinemia | Low FSH, low LH | Check prolactin, MRI pituitary | | Thyroid dysfunction | Indirectly affects cycle regularity | Check TSH alongside FSH in any workup for irregular cycles | | Endometriosis | FSH usually normal; AMH may be low post-surgery | Antral follicle count and AMH are better ovarian reserve markers |

FSH in perimenopause and menopause: what you actually need to know

Perimenopause is the most common reason women find themselves looking at an FSH result without clear guidance on what to do with it.

Why a single high FSH does not confirm menopause

The ovaries during perimenopause are not failing uniformly. They may produce very little estradiol one month (causing a high FSH and hot flashes) and then recruit an active follicle the next month (suppressing FSH back below 10 mIU/mL and possibly triggering ovulation). This is why ACOG advises against using FSH alone to diagnose menopause and why a woman in her late 40s with a single "menopausal" FSH still needs reliable contraception.

Contraception in perimenopause: a critical FSH-related safety point

Spontaneous ovulation can occur even with FSH above 25 mIU/mL in perimenopause. ACOG recommends continuing contraception until 12 consecutive months of amenorrhea in women over 50, or 24 months in women under 50. A "menopausal" FSH result is not a green light to stop birth control.

Using FSH to guide hormone therapy decisions

Menopausal hormone therapy (MHT) suppresses FSH. Once a woman starts MHT, FSH testing loses most of its value for confirming menopause or monitoring adequacy of therapy. Symptom control, not FSH numbers, should guide MHT dose adjustments.

FSH and fertility treatment: what your number means for your protocol

If you are working with a reproductive endocrinologist, your day-3 FSH result shapes your ovarian stimulation protocol more than almost any other single variable.

Day-3 FSH thresholds that matter in IVF

Many IVF programs use a day-3 FSH of <10 mIU/mL as a threshold for proceeding with a standard stimulation protocol. Values of 10-15 mIU/mL may prompt a higher starting dose of injectable FSH. Values above 15-20 mIU/mL are associated with poor ovarian response and lower live birth rates per cycle, though they do not make conception impossible. The POSEIDON (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) classification used in many fertility centers incorporates FSH alongside age, AMH, and antral follicle count to categorize poor responders and guide individualized protocols.

FSH variability cycle to cycle

FSH can vary by as much as 3-5 mIU/mL between cycles in the same woman. A single elevated result should generally be confirmed with a repeat before making major treatment decisions. Some programs draw FSH and estradiol together, because an elevated estradiol on day 3 (above 60-80 pg/mL) can suppress FSH and give a falsely reassuring low result.

How your menstrual cycle affects FSH (and why cycle day matters so much)

FSH is not a static hormone. Its blood level changes every day of your cycle.

• Day 2-3 (early follicular): lowest of the cycle; the standard time to measure ovarian reserve
• Day 7-10 (late follicular): rising estradiol begins to suppress FSH; values drop below day-3 level in normal responders
• Day 12-14 (periovulatory): FSH surges alongside the LH surge to trigger final follicle maturation
• Day 15-28 (luteal phase): FSH falls to its lowest point; measuring it here is not informative for any clinical question

If your doctor ordered FSH and you do not know what day of your cycle it was drawn, contact the ordering office. The result may need to be redrawn on day 2-3.

Pregnancy and testing considerations

FSH testing is not performed in pregnancy and has no role in prenatal care. Once the embryo implants, hCG production suppresses all pituitary gonadotropins. FSH becomes undetectable or near-undetectable within days of a positive pregnancy test.

For women who have received injectable FSH as part of fertility treatment (such as Gonal-F, Follistim, or Menopur), these exogenous FSH preparations cross the placenta in small amounts but are not associated with fetal harm at ovarian stimulation doses, based on existing registry data. Exogenous FSH is used only during the stimulation phase before egg retrieval; exposure during an established pregnancy does not occur under standard IVF protocols.

Women with POI or premature ovarian insufficiency who conceive (spontaneously or via donor egg) have pregnancies managed identically to age-matched peers for most obstetric purposes, though cardiovascular monitoring may be warranted given the longer duration of estrogen deficiency many of these women experience before conception.

Who should get FSH tested (and who does not need it)

Strong clinical indications

• Irregular or absent periods at any age outside of pregnancy
• Evaluation of infertility (always draw on cycle day 2-3, with LH and estradiol)
• Suspicion of perimenopause or POI
• Evaluation of delayed or precocious puberty
• Monitoring of known pituitary or hypothalamic disease
• Before starting or adjusting ovarian stimulation in fertility treatment

Situations where FSH adds little

• Routine annual wellness labs in a woman with regular cycles and no fertility concerns
• Monitoring adequacy of menopausal hormone therapy (symptoms are a better guide)
• A single borderline result without clinical context
• Pregnancy

Life-stage guidance at a glance

• Teens with delayed puberty or irregular cycles: FSH plus LH, estradiol, prolactin, and TSH together
• Reproductive years, trying to conceive: Day-3 FSH plus AMH, antral follicle count, and estradiol
• Perimenopause: FSH with symptom diary; repeat if borderline; do not stop contraception based on FSH alone
• Postmenopause: Test only if pituitary disease is suspected or diagnosis is uncertain

Evidence gaps: what we still do not know about FSH in women

Women have been underrepresented in the pituitary and gonadotropin research that established FSH reference ranges. Most foundational FSH studies used populations that were predominantly White and of European ancestry. Emerging data suggest FSH reference ranges may differ modestly by ethnicity, as seen in the SWAN study cohort, which included Black, Hispanic, Chinese, and Japanese women alongside White women and found differences in FSH trajectories across the menopausal transition.

Reference ranges used by commercial labs are often derived from small manufacturer studies, not large prospective cohorts. When your result sits near the boundary of "normal" and "abnormal," the clinical picture, your symptoms, your cycle history, and your other hormone levels, matters more than the printed cutoff.

The long-term cardiovascular significance of elevated FSH in postmenopausal women is an active research area. Some observational studies suggest that FSH itself (not just estrogen deficiency) may influence bone metabolism and adipose tissue distribution, but this is not yet incorporated into clinical guidelines.